反应详情

The title compound (13 mg, 12%) was prepared from {4-[(cyclopropylamino)carbonyl]phenyl}boronic acid (41 mg, 0.2 mmol), 1-methylethyl 4-{[(4-bromophenyl)oxy]methyl}-1-piperidinecarboxylate (prepared as in Example 9, Step 2, 71 mg, 0.2 mmol), Pd(PPh3)2Cl2 (50 mg, 0.07 mmol), 2M Na2CO3 (1 mL) and DME (1 mL) in a manner similar to Example 21, Step 3, and worked up in a manner similar to Example 9, Step 3. 1H NMR (400 MHz, CDCl3): δ 7.77 (d, 2H, J=8.4 Hz), 7.59 (d, 2H, J=8.6 Hz), 7.53 (d, 2H, J=8.8 Hz), 6.96 (d, 2H, J=8.8 Hz), 6.24 (s, 1H), 4.97-4.84 (m, 1H), 4.21 (bs, 2H), 3.84 (d, 2H, J=6.4 Hz), 2.96-2.86 (m, 1H), 2.83-2.73 (m, 2H), 2.05-1.95 (m, 1H), 1.90-1.80 (m, 2H), 1.36-1.26 (m, 2H), 1.24 (d, 6H, J=6.4 Hz), 0.93-0.84 (m, 2H), 0.66-0.60 (m, 2H); LRMS (ESI), m/z 437 (M+H).